Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


suck pdf from google scholar
unlimited free pdf from europmc32579907    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32579907  :  Publisher
PDF vom PMID32579907 :   free
PDF vom PMID32579907

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • Paromomycin: A potential dual targeted drug effectively inhibits both spike (S1) and main protease of COVID-19 #MMPMID32579907
  • Tariq A; Mateen RM; Afzal MS; Saleem M
  • Int J Infect Dis 2020[Sep]; 98 (ä): 166-175 PMID32579907show ga
  • OBJECTIVES: With the increasing number of people suffering from coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a dire need to look for effective remedies against this pandemic. Drug repurposing seems to be the solution for the current situation. METHODS: In a quest to find a potential drug against this virus, 15 antimalarial drugs (including chloroquine) and 2413 US Food and Drug Administration-approved drugs were investigated for activity against both the protease and spike proteins of SARS-CoV-2 using an in silico approach. Molecular docking analysis followed by molecular dynamics simulation was performed to estimate the binding and stability of the complexes. RESULTS: This study identified a single drug - paromomycin - with activity against two targets of SARS-CoV-2, i.e., spike protein (S1) and protease domain. Paromomycin was found to have strong binding affinity for both targets of coronavirus. The results also showed that no antimalarial drug exhibited effective binding for either S1 or protease. CONCLUSIONS: This study found that paromomycin may be an effective dual targeting drug against coronavirus, as it binds not only to the protease domain of the virion, but also to the spike domain, with high stability. Furthermore, none of the antimalarial drugs showed strong binding affinity for either protease or the receptor binding domain (RBD).
  • |Betacoronavirus/*drug effects/metabolism[MESH]
  • |Computer Simulation[MESH]
  • |Coronavirus Infections/*drug therapy[MESH]
  • |Drug Repositioning[MESH]
  • |Humans[MESH]
  • |Molecular Docking Simulation[MESH]
  • |Pandemics[MESH]
  • |Paromomycin/*therapeutic use[MESH]
  • |Peptide Hydrolases/chemistry/*metabolism[MESH]
  • |Pneumonia, Viral/*drug therapy[MESH]
  • |Protease Inhibitors/*therapeutic use[MESH]
  • |Protein Binding[MESH]
  • |Spike Glycoprotein, Coronavirus/*antagonists & inhibitors[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    166 ä.98 2020